NYSEAMERICAN:DXR - Daxor Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 71.27 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$12.85
▼ -0.21 (-1.61%)
1 month | 3 months | 12 months
Get New Daxor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.00
▲ +71.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Daxor in the last 3 months. The average price target is $22.00, with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 71.27% upside from the last price of $12.85.
Buy
The current consensus among 1 investment analysts is to buy stock in Daxor. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
9/2/2020Maxim GroupReiterated RatingBuy$22.00
i
9/30/2019Roth CapitalReiterated RatingNeutral
i
Rating by S. Henry at Roth Capital
9/30/2019Roth CapitalInitiated CoverageNeutral$18.00
i
7/29/2019Maxim GroupInitiated CoverageBuy$22.00
i
5/16/2019Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$20.00
i
(Data available from 1/22/2016 forward)
Daxor logo
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Read More

Today's Range

Now: $12.85
$12.85
$12.85

50 Day Range

MA: $12.75
$12.41
$13.20

52 Week Range

Now: $12.85
$7.85
$24.08

Volume

393 shs

Average Volume

2,521 shs

Market Capitalization

$49.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Daxor?

The following Wall Street analysts have issued stock ratings on Daxor in the last twelve months: Maxim Group, and Zacks Investment Research.

What is the current price target for Daxor?

1 Wall Street analysts have set twelve-month price targets for Daxor in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 71.3%. Maxim Group has the highest price target set, predicting DXR will reach $22.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $22.00 for Daxor in the next year.

What is the current consensus analyst rating for Daxor?

Daxor currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXR will outperform the market and that investors should add to their positions of Daxor.

What other companies compete with Daxor?

How do I contact Daxor's investor relations team?

Daxor's physical mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company's listed phone number is +1-212-3308500 and its investor relations email address is dmeegan[email protected] The official website for Daxor is www.daxor.com.